Alpha-fetoprotein-L3 in hepatocellular carcinoma: A meta-analysis

Clinica Chimica Acta

Volumn 425, Issue , 2013, Pages 212-220

  Yi, Xiaoyan ^a   Yu, Shuang ^a   Bao, Yixi ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

AFP L3; Diagnosis; Hepatocellular carcinoma; Meta analysis

Indexed keywords

ALPHA FETOPROTEIN; ISOPROTEIN; LENS CULINARIS AGGLUTININ REACTIVE ALPHA FETOPROTEIN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; DIAGNOSTIC VALUE; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

AFP-L3; DIAGNOSIS; HEPATOCELLULAR CARCINOMA; META-ANALYSIS;

ALPHA-FETOPROTEINS; AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; DATABASES, BIBLIOGRAPHIC; HUMANS; LIVER NEOPLASMS; ODDS RATIO; PLANT LECTINS; PREDICTIVE VALUE OF TESTS; PROTEIN ISOFORMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84883417778     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.08.005     Document Type: Review

References (60)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
3. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
4. Kudo M. The 2008 Okuda lecture: management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010, 25:439-452.
5. Trevisani F., D'Intino P.E., Morselli-Labate A.M., et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001, 34:570-575.
6. Gambarin-Gelwan M., Wolf D.C., Shapiro R., Schwartz M.E., Min A.D. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 2000, 95:1535-1538.
7. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology 1990, 12:1420-1432.
8. Caroline D.M.W., van A S.M., Steyerberg E.W., et al. Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hep Intl 2013, 7:59-64.
9. Sato Y., Nakata K., Kato Y., et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993, 328:1802-1806.
10. Sterling R.K., Jeffers L., Gordon F., et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol 2007, 102:2196-2205.
11. Toshiyuki T., Shinji S., Tatsuhiro Y., et al. Lectin-reactive α-fetoprotein (AFP-L3%) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors. Jpn J Clin Oncol 2001, 32:472-476.
12. Hayashi K., Kumada T., Nakano S., et al. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 1999, 94:3028-3033.
13. Okuda K., Tanaka M., Kanazawa N., et al. Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein. Int J Oncol 1999, 14:265-271.
14. Shiraki K., Takase K., Tameda Y., Hamada M., Kosaka Y., Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995, 22:802-807.
15. Taketa K., Endo Y., Sekiya C., et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993, 53:5419-5423.
16. Yamashita F., Tanaka M., Satomura S., Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996, 111:996-1001.
17. Choi J.Y., Jung S.W., Kim H.Y., et al. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J Gastroenterol 2013, 19:339-346.
18. Kagebayashi C., Yamaguchi I., Akinaga A., et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 2009, 388:306-311.
19. Whiting P.F., Rutjes A.W.S., Westwood M.E., et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011, 155:529-536.
20. Zamora J., Abraira V., Muriel A., Khan K., Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006, 6:31.
21. Choi J., Park Y., Kim J.-H., Kim H.-S. Evaluation of revisited fucosylated alpha-fetoprotein (AFP-L3) with an autoanalyzer μTAS in a clinical laboratory. Clin Chim Acta 2012, 413:170-174.
22. Durazo F.A., Blatt L.M., Corey W.G., et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2008, 23:1541-1548.
23. Leerapun A., Suravarapu S.V., Bida J.P., et al. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma evaluation in a United States referral population. Clin Gastroenterol Hepatol 2007, 5:394-402.
24. Marrero J.A., Feng Z., Wang Y., et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009, 137:110-118.
25. Oda K., Ido A., Tamai T., et al. Highly sensitive lens culinaris agglutinin-reactive alpha-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease. Oncol Rep 2011, 26:1227-1233.
26. Qu K.Z., Zhang K., Li H.R., et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011, 45:355-360.
27. Shimizu A., Shiraki K., Ito T., et al. Sequential fluctuation pattern of serum des-γ-carboxy prothrombin levels detected by high-sensitive electro-chemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis. Int J Mol Med 2002, 9:245-250.
28. Sterling R.K., Jeffers L., Gordon F., et al. Utility of Lens culinaris agglutinin-reactive fraction of α-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009, 7:104-113.
29. Tamura Y., Igarashi M., Kawai H., Suda T., Satomura S., Aoyagi Y. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci 2010, 55:3576-3583.
30. Tanwandee T., Setthasin S., Charatcharoenwitthaya P., et al. Clinical utility of lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma evaluation in a Thai referral population. J Med Assoc Thai 2009, 92:49-56.
31. Volk M.L., Hemandez J.C., Su G.L., et al. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomarker 2007, 3:79-87.
32. Zinkin N.T., Grall F., Bhaskar K., et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008, 14:470-477.
33. Baumann U., Duhme V., Auth M.K.H., et al. Lectin-reactive alpha-fetoprotein in patients with tyrosinemia type I and hepatocellular carcinoma. J Pediatr Gastroenterol Nutr 2006, 43:77-82.
34. Carr B.I., Kanke F., Wise M., Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007, 52:776-782.
35. Cheng H.-T., Chang Y.-H., Chen Y.-Y., Lee T.-H., Tai D.-I., Lin D.-Y. AFP-L3 in chronic liver diseases with persistent elevation of alpha-fetoprotein. J Clin Med Assoc 2007, 70:310-317.
36. Choi J.Y. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J Gastroenterol 2013, 19:339.
37. Hadziyannis E. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels. Oncol Rep 2013, 29:835-839.
38. Hanaoka T., Sato S., Tobita H., et al. Clinical significance of the highly sensitive fucosylated fraction of alpha-fetoprotein in patients with chronic liver disease. J Gastroenterol Hepatol 2011, 26:739-744.
39. Kanmura S., Uto H., Sato Y., et al. The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol 2010, 45:459-467.
40. Khien V.V., Mao H.V., Chinh T.T., et al. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers 2001, 16:105-111.
41. Kumada T., Toyoda H., Kiriyama S., et al. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol 2011, 46:536-544.
42. Miura N., Osaki Y., Nagashima M., et al. A novel biomarker TERTmRNA is applicable for early detection of hepatoma. BMC Gastroenterol 2010, 10:46.
43. Moriya S., Morimoto M., Numata K., et al. Fucosylated fraction of alpha-fetoprotein as a serological marker of early hepatocellular carcinoma. Anticancer Res 2013, 33:997-1001.
44. Morimoto M., Numata K., Nozaki A., et al. Novel Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low alpha-fetoprotein concentrations. Int J Clin Oncol 2012, 17:373-379.
45. Nouso K., Kobayashi Y., Nakamura S., et al. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol 2011, 26:1195-1200.
46. Oka H., Saito A., Ito K., et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive α-fetoprotein. J Gastroenterol Hepatol 2001, 16:1378-1383.
47. Qu K.Z., Zhang K., Ma W., et al. Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease. J Gastroenterol Hepatol 2011, 26:751-758.
48. Shimauchi Y., Tanaka M., Kuromatsu R., et al. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep 2000, 7:249-256.
49. Sterling R.K., Wright E.C., Morgan T.R., et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2012, 107:64-74.
50. Subwongcharoen S., Leelawat K., Treepongkaruna S.A., et al. Serum AFP and AFP-L3 in clinically distinguished hepatocellular carcinoma from patients with liver masses. J Med Assoc Thai 2011, 94:46-51.
51. Taketa K., Okada S., Win N., et al. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar. Acta Med Okayama 2002, 56:317-320.
52. Tameda M., Shiraki K., Sugimoto K., et al. Des-gamma-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma. Cancer Sci 2013, 104:725-731.
53. Tamura Y., Suda T., Arii S., et al. Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment. Dig Dis Sci 2013, 58.
54. Toyoda H., Kumada T., Kaneoka Y., et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol 2008, 49:223-232.
55. Toyoda H., Kumada T., Tada T., et al. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20ng/mL. Cancer Sci 2011, 102:1025-1031.
56. Wang W., Zhao L.J., Wang Y., et al. Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC. Cancer Biomark 2011, 11:29-39.
57. Yamagata Y., Shimizu K., Nakamura K., et al. Simultaneous determination of percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein and alpha-fetoprotein concentration using the LiBASys clinical auto-analyzer. Clin Chim Acta 2003, 327:59-67.
58. Yoshida S., Kurokohchi K., Arima K., et al. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol 2002, 20:305-309.
59. Zhang X.F., Yin Z.F., Wang K., et al. Changes of serum alpha-fetoprotein and alpha-fetoprotein-L3 after hepatectomy for hepatocellular carcinoma: prognostic significance. Hepatobiliary Pancreat Dis Int 2012, 11:618-623.
60. Kawabata T., Wada H.G., Watanabe M., Satomura S. Electrokinetic analyte transport assay for alpha-fetoprotein immunoassay integrates mixing, reaction and separation on-chip. Electrophoresis 2008, 29:1399-1406.